Seeking Alpha

Cel-Sci (CVM +6.9%) CEO Geert Kersten drops heavy hints that the firm's Multikine treatment for...

Cel-Sci (CVM +6.9%) CEO Geert Kersten drops heavy hints that the firm's Multikine treatment for head and neck cancer is performing well in Phase 3 trials. "Based on everything that we've seen in the clinic so far, if we continue to see the same results, we will have the first non-toxic cancer therapy," Kersten tells eHealth Radio.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|